journal article·2014-09Open access

Potentiation of pH-sensitive polymer-modified liposomes with cationic lipid inclusion as antigen delivery carriers for cancer immunotherapy

Yuta Yoshizaki, Eiji Yuba, Naoki Sakaguchi, Kazunori Koiwai, Atsushi Harada, Kenji Kono

Biomaterials· Volume 35· Issue 28

Abstract

Cationic lipid-incorporated liposomes modified with pH-sensitive polymers were prepared by introducing 3, 5-didodecyloxybenzamidine as a cationic lipid to egg yolk phosphatidylcholine liposomes modified with 3-methylglutarylated hyperbranched poly(glycidol) (MGlu-HPG) as a pH-sensitive polymer. These liposomes were stable at neutral pH, but were destabilized below pH 6.0 because MGlu-HPG changed its characteristics from hydrophilic to hydrophobic in response to the pH decrease. Cationic lipid inclusion improved their pH sensitivity at weakly acidic pH and association of liposomes with murine dendritic cell (DC) lines. Cationic lipid-incorporated liposomes delivered entrapped ovalbumin (OVA) molecules not only to cytosol but also to endosome/lysosome. Treatment with cationic lipid-incorporated liposomes induced up-regulation of antigen presentation-involved molecules on DCs, the promotion of cytokine production, and antigen presentation via both major histocompatibility complex (MHC) class I and II molecules. Especially, antigen presentation via MHC class II was promoted by cationic lipid inclusion, which might correspond to efficient endosome/lysosome delivery of OVA. Subcutaneous administration of OVA-loaded cationic lipid-incorporated liposomes induced antigen-specific antibody production in serum and Th1-dominant immune responses in the spleen. Furthermore, administration of the cationic lipid-incorporated liposomes to mice bearing E.G7-OVA tumor more significantly reduced the tumor volume than liposomes without cationic lipids. Therefore, cationic lipid inclusion into pH-sensitive polymer-modified liposomes, which can achieve both efficient antigen intracellular delivery and activation of antigen presenting cell, is an effective approach to develop antigen carriers for efficient cancer immunotherapy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Immunotherapy and Immune Responses · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (48)

Show source-provided references
1. Dendritic cells as therapeutic vaccines against cancer10.1038/nri1592 ↗
2. Cancer immunotherapy comes of age10.1038/nature10673 ↗
3. Dendritic cells in cancer immunotherapy10.1146/annurev.immunol.18.1.245 ↗
4. Novel tumor immunotherapy: targeting dysfunctional antigen presenting cells
5. Cancer immunotherapy via dendritic cells10.1038/nrc3258 ↗
6. Dendritic cells and the control of immunity10.1038/32588 ↗
7. Dendritic cells: specialized and regulated antigen processing machines10.1016/S0092-8674(01)00449-4 ↗
8. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery10.1096/fj.02-0088com ↗
9. Biodegradable nanoparticles as vaccine adjuvants and delivery systems: regulation of immune responses by nanoparticle-based vaccine10.1007/12_2011_150 ↗
10. In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants10.1021/mp900311x ↗
11. Sendai virus fusion protein mediates simultaneous induction of MHC class I/II-dependent mucosal and systemic immune responses via the nasopharyngeal-associated lymphoreticular tissue immune system10.4049/jimmunol.167.3.1406 ↗
12. Virosome mediated delivery of protein antigens to dendritic cells10.1016/S0264-410X(02)00103-2 ↗
13. pH-sensitive liposomes provide an efficient means of sensitizing target cells to class I restricted CTL recognition of a soluble protein10.1016/0022-1759(91)90142-3 ↗
14. Intracellular regulation of macromolecules using pH-sensitive liposomes and nuclear localization signal: qualitative and quantitative evaluation of intracellular trafficking10.1006/bbrc.1998.9460 ↗
15. A liposome-based antigen delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy10.1016/j.biomaterials.2012.12.031 ↗
16. pH-Dependent complexation of poly(acrylic acid) derivatives with phospholipid vesicle membrane10.1021/ma00139a009 ↗
17. The design and synthesis of polymers for eukaryotic membrane disruption10.1016/S0168-3659(99)00114-5 ↗
18. Efficient MHC class I presentation by controlled intracellular trafficking of antigens in octaarginine-modified liposomes10.1038/mt.2008.122 ↗
19. Cytoplasmic delivery of calcein mediated by liposomes modified with a pH-sensitive poly(ethylene glycol) derivative10.1016/S0005-2736(96)00244-1 ↗
20. Preparation of pH-sensitive poly(glycidol) derivatives with varying hydrophobicities: their ability to sensitize stable liposomes to pH10.1021/bc7004736 ↗
21. Carboxylated hyperbranched poly(glycidol)s for preparation of pH-sensitive liposomes10.1016/j.jconrel.2010.03.001 ↗
22. Dextran derivative-based pH-sensitive liposomes for cancer immunotherapy10.1016/j.biomaterials.2013.12.024 ↗
23. T cell anergy and costimulation10.1034/j.1600-065X.2003.00009.x ↗
24. The role of B7 costimulation in T-cell immunity10.1046/j.1440-1711.1999.00835.x ↗
25. A three-cell model for activation of naïve T helper cells10.1111/j.1365-3083.2006.01782.x ↗
26. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells
27. Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation10.1182/blood.V98.5.1512 ↗
28. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR410.1126/science.1138963 ↗
29. CpG DNA induces stronger immune responses with less toxicity than other adjuvants10.1016/S0264-410X(99)00526-5 ↗
30. Effects of β-glucans on the immune system10.3390/medicina43080076 ↗
31. Cationic lipids activate intracellular signaling pathways10.1016/j.addr.2012.05.009 ↗
32. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid10.1007/s00262-007-0390-4 ↗
33. Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine10.1007/s00262-011-0970-1 ↗
34. Trp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model10.1021/mp200350n ↗
35. Gene delivery to dendritic cells mediated by complexes of lipoplexes and pH-sensitive fusogenic polymer-modified liposomes10.1016/j.jconrel.2008.05.007 ↗
36. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules10.4049/jimmunol.158.6.2723 ↗
37. Introduction of soluble protein into the class I pathway of antigen processing and presentation10.1016/S0092-8674(88)91043-4 ↗
38. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules10.4049/jimmunol.153.11.4925 ↗
39. Delivery of exogenous antigen into the major histocompatibility complex class I and class II pathways by electroporation10.1002/jlb.56.5.616 ↗
40. Endocytosis of liposomes by macrophages: binding, acidification and leakage of liposomes monitored by a new fluorescence assay10.1016/0005-2736(90)90365-U ↗
41. A statistically defined endpoint titer determination method for immunoassays10.1016/S0022-1759(98)00170-7 ↗
42. Immature dendritic cells phagocytose apoptotic cells via avb5 and CD36, and cross-present antigens to cytotoxic T lymphocytes10.1084/jem.188.7.1359 ↗
43. Receptor-mediated endocytosis of poly(acrylic acid)-conjugated liposomes by macrophages10.1016/0005-2736(95)00183-2 ↗
44. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease
45. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions10.1002/eji.1830271209 ↗
46. CpG ODN mediated prevention from ovalbumin-induced anaphylaxis in mouse through B cell pathway10.1016/j.intimp.2007.10.019 ↗
47. Compatibility of plasmids expressing different antigens in a single DNA vaccine formulation10.1099/0022-1317-79-12-2965 ↗
48. The safety evaluation of adjuvants during vaccine development: The AS04 experience10.1016/j.vaccine.2011.04.046 ↗